AzTrials
AzTrials

HIV-1-infectionPhase 1/2NCT06336434

CREATE - Cabotegravir & Rilpivirine Antiretroviral Therapy in Pregnancy

A Phase 1/2 study testing CAB LA 600mg, RPV LA 900mg and CAB LA 400mg in people with HIV-1-infection and Pregnancy, run by National Institute of Allergy and Infectious Diseases (NIAID) at 8 sites in 2 countries.

Withdrawn

Withdrawn. The study stopped before anyone enrolled.

Official record
Search all trials

Trial summary

This is a Phase I/II, multicenter, open-label, non-randomized study with four groups to characterize the pharmacokinetics and safety of Cabotegravir (CAB) and Rilpivirine (RPV) long-acting injectable (LA) during pregnancy and postpartum among people with HIV-1 viral suppression and their infants. Read more about this study

Who is it for?
Ages 18 years and older, women only
Conditions the study is for
HIV-1-infection, Pregnancy, Postpartum
What is being tested?
CAB LA 600mg, RPV LA 900mg and CAB LA 400mg
Could I receive a placebo?
No, everyone receives an active treatment
How many people
0 participants
Where
8 sitesin 2 countries
Study dates
1 May 2025to 30 Jan 2028
Phase
Phase 1/2
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • Women only
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Willing and able to provide written informed consent for study participation for self and infant.
  • Note: All sites must follow all applicable IRB/EC policies and procedures; for US sites, this includes single IRB (sIRB) policies and procedures.
  • At screening, age 18 years or older.
  • At entry, evidence of a viable, intrauterine, singleton pregnancy with fetal ultrasound performed per protocol and within the following estimated gestational age (EGA) ranges per protocol:
  • Switch Group: EGA between 10 0/7 and 19 4/7 weeks (inclusive) at entry.
  • Continuation Group: EGA less than or equal to 19 4/7 weeks at entry.
Show all 52Show fewer
  • Note: If adequate ultrasound results are not available from medical records at screening per protocol, an ultrasound must be performed prior to study entry.
  • At entry, intending to deliver at a study-associated medical facility, remain in the geographic area of the study for the duration of anticipated follow-up, and attend regularly scheduled study visits.
  • Confirmed HIV-1 infection based on documented testing of two samples collected from two separate blood collection tubes per Sample #1 and Sample #2 requirements. Test results may be obtained from medical records or from testing performed at screening (i.e., from specimens collected within 28 days prior to entry):
  • For results obtained from medical records, adequate source documentation, including the date of specimen collection, date of testing or date of test result, name of test/assay performed, and test result, must be available in study records prior to study entry. Requirements related to laboratory operations (e.g., Good Clinical Laboratory Practice [GCLP], Clinical Laboratory Improvement Amendments [CLIA], Virology Quality Assurance [VQA]) and related to regulatory authority approvals (e.g., FDA) do not apply to results obtained from medical records.
  • If adequate source documentation is not available, Sample #1 and/or Sample #2 should be collected during the study screening period and tested in the site's designated testing laboratory.
  • If both samples are tested using antibody tests, at least one of the samples must be tested in a laboratory that operates according to CLIA or equivalent (for US sites) or GCLP (for South African sites) guidelines and participates in an appropriate external quality assurance program. If nucleic acid testing (NAT) is used, at least one test must be performed in the site's CLIA-certified or equivalent (for US sites) or VQA-certified (for South African sites) laboratory.
  • Sample #1 may be tested using any of the following:
  • Two rapid antibody-based tests from different manufacturers or based on different principles and epitopes (combination antigen-antibody-based rapid tests may be used)
  • One enzyme immunoassay (EIA) or Western blot (WB) or immunofluorescence assay or chemiluminescence assay
  • One HIV-1 DNA polymerase chain reaction (PCR)
  • One quantitative HIV-1 RNA PCR (above the limit of detection of the assay)
  • One qualitative HIV-1 RNA PCR
  • One HIV-1 total NAT
  • Sample #2 may be tested using any of the following:
  • Rapid antibody-based test. If this option is used in combination with two rapid tests for Sample
  • #1, at least one of the three rapid tests must be FDA-approved and the third rapid test must be from a third manufacturer or based on a third principle or epitope. Combination antigen-antibody based rapid tests may be used.
  • One EIA or WB or immunofluorescence assay or chemiluminescence assay
  • One HIV-1 DNA PCR
  • One quantitative HIV-1 RNA PCR (above the limit of detection of the assay)
  • One qualitative HIV-1 RNA PCR
  • One HIV-1 total NAT
  • All study-specific samples tested to determine HIV-1 status must be whole blood, serum, or plasma.
  • HIV-1 testing methods and algorithms must be approved for each site by the IMPAACT Laboratory Center (for NIAID-funded sites) or Westat (for NICHD-funded ods should be FDA-approved, if available.
  • Has at least one documented plasma HIV-1 RNA result less than 50 copies/mL or less than the lower limit of detection from the assay, from a specimen collected in the three to nine months (defined as 90-270 days) prior to entry.
  • Note: See Exclusion Criterion 4.2.1 for additional criterion that must be evaluated to confirm adequate viral suppression prior to entry.
  • Documented plasma HIV-1 RNA result less than 50 copies/mL at screening (i.e., from a specimen collected within 28 days prior to entry).
  • Note: HIV-1 RNA laboratory tests may be repeated if the result is greater than or equal to 50 copies/mL but less than 200 copies/mL during the study screening period, with the latest result used for eligibility determination. The repeat viral load testing should be conducted within two weeks (14 days) of the initial sample collection.
  • Has no evidence of hepatitis B infection based on hepatitis B surface antigen (HBsAg), hepatitis B core antibody (HbcAb), and hepatitis B surface antibody (HbsAb) testing at screening (i.e., from a specimen collected within 28 days prior to entry); any of the following three combinations of test results are acceptable for inclusion:
  • HbsAg negative, HbcAb negative, HbsAb negative
  • HbsAg negative, HbcAb negative, HbsAb positive
  • HbsAg negative, HbcAb positive, HbsAb positive
  • Negative hepatitis C antibody (anti-HCV ab) test result at screening (i.e., from a specimen collected within 28 days prior to entry).
  • Has the following laboratory test results at screening (i.e., from a specimen collected within 28 days prior to entry) based on grading per protocol:
  • Grade 2 or lower platelets (greater than or equal to 50,000 cells/mm3 or greater than or equal to 50.00 x 109 cells/L)
  • Grade 2 or lower creatinine (less than or equal to 1.8 x upper limit of normal [ULN])
  • Grade 2 or lower total bilirubin (less than 2.6 x ULN)
  • Grade 1 or lower ALT (less than 2.5 x ULN)
  • Grade 1 or lower aspartate aminotransferase (AST) (less than 2.5 x ULN)
  • Grade 1 or lower absolute neutrophil count (ANC) (greater than or equal to 800 cells/mm3)
  • Grade 2 or lower hemoglobin (greater than or equal to 8.5 g/dL)
  • Grade 2 or lower lipase (less than 3 x ULN)
  • Note: Laboratory tests may be repeated during the study screening period (i.e., within 28 days prior to entry), with the latest result used for eligibility determination.
  • Has a Grade 1 or lower QT interval corrected by the Fridericia formula (QTcF) (mean interval value less than or equal to 470 milliseconds, on ECG performed in triplicate) at screening.
  • For Switch Group, on a stable (i.e., unchanged) oral ART regimen for at least 90 consecutive days prior to entry, as determined by the site investigator based on participant report and available medical records.
  • Note: Changes of formulation (e.g., from a single agent to fixed dose combination tables) and of boosting agents (e.g., from cobicistat to ritonavir) are permitted.
  • For Continuation Group, received first dose of CAB LA + RPV LA on or before the date of conception of the current pregnancy based on guidelines in protocol, has not changed regimens since the time of conception, and is on the appropriate maintenance doses for Q4W or Q8W dosing at screening, as determined by the site investigator based on participant report and available medical records.

Who cannot join

  • Within nine months (270 days) prior to entry, any plasma HIV-1 RNA measurement greater than or equal to 200 copies/mL or two or more detectable plasma HIV-1 RNA measurements greater than or equal to 50 copies/mL at least 14 days apart.
  • History of treatment/virologic failure associated with documented or presumed viral resistance to NNRTI or INSTI, defined as two consecutive plasma HIV-1 RNA measurements greater than or equal to 200 copies/mL after initial suppression to less than 50 copies/mL.
  • Has any of the following, as determined by the site investigator based on participant report, clinical evidence, and/or available antenatal/medical care records:
  • Historical or suspected resistance to NNRTI and INSTI classes, (i.e., presence of NNRTI and/or INSTI resistance associated substitutions or a phenotype resistance result to any NNRTI and/ or INSTI).
  • Note: If there are questions regarding suspected resistance, the site investigator should consult with the CMC prior to enrolling the participant.
  • HIV-1 Subtype A6
Show all 38Show fewer
  • Hypersensitivity reaction (HSR), known or suspected allergy to study product components, or any other contraindication to CAB or RPV.
  • Contraindication to IM injection such as a current inflammatory skin condition that compromises the safety of IM injections or a dermatological condition which, may interfere with the interpretation of ISRs (including but not limited to gluteal implants).
  • Note: Use of the proper needle length based on participant body size and shape is essential to ensure correct IM injection technique. See protocol for more information. High body mass index (BMI) is not considered exclusionary.
  • Known ARV treatment interruption (greater than 30 consecutive days) in the 24 months prior to entry.
  • For participants on EFV, known treatment interruption (greater than seven consecutive days) in the 24 months prior to entry.
  • Any use of Nevirapine (ever), including, but not limited to a short course regimen to prevent perinatal transmission.
  • At entry, current use or anticipated need of therapeutic anticoagulation (e.g., low molecular weight heparin, coumadin, heparin, or enoxaparin).
  • History of known or suspected bleeding disorder.
  • Current severe hepatic impairment (Class C) as determined by Child-Pugh classification.
  • Suicidal ideation or attempt within six months of entry, based on completion of the Columbia-Suicide Severity Rating Scale (C-SSRS).
  • Unstable or poorly controlled seizure disorder.
  • Known tuberculosis infection.
  • Ongoing malignancy other than Kaposi's sarcoma, basal cell carcinoma, or resected, non-invasive cutaneous squamous cell carcinoma, or cervical intraepithelial neoplasia.
  • Symptoms suggestive of active coronavirus disease 2019 (COVID-19) or test results or contacts that require isolation or quarantine per local clinical practice, public health, and/or infection control guidelines.
  • Note: Potential participants with symptoms suggestive of active COVID-19, test results, and/or contacts that require quarantine may resume screening (or be re-screened) after symptoms have resolved and applicable quarantine requirements have been completed.
  • Known to have any of the following during the current pregnancy as determined by the site investigator based upon participant report, clinical evidence, and/or available antenatal/medical care records:
  • Multiple gestation
  • Abnormal placentation, including placenta previa (complete) and placenta accreta/increta/percreta
  • Cervical cerclage/cervical incompetence
  • Abnormal fetal anatomy (in the opinion of the site investigator)
  • Known to have had any of the following in a previous pregnancy as determined by the site investigator based upon participant report, clinical evidence, and/or available antenatal/medical care records:
  • Eclampsia/Hemolysis, Elevated Liver enzymes and Low Platelets (HELLP) syndrome
  • Intrauterine fetal demise (EGA greater than 20 weeks) without known non- recurrent etiology
  • Spontaneous very preterm delivery (less than 32 weeks)
  • Very low birth weight (LBW) (less than 1500 g)
  • Cervical or abdominal cerclage due to cervical incompetence
  • At entry, has uncontrolled pregnancy-related comorbidities (e.g., diabetes with fasting blood glucose greater than 200, hypertension with recurrent systolic greater than or equal to 160 or diastolic greater than 100) per the discretion of the site investigator.
  • Receipt of any prohibited medication within seven days prior to entry, with the exception of antiviral agents that are part of the participant's ART regimen, as determined by the site investigator based on participant report and available medical records, see Appendix IV.
  • Note: Medications and vaccines approved for emergency use (e.g., COVID vaccines) that do not appear in the IMPAACT 2040 Prohibited and Precautionary Medications listing are not exclusionary and may be administered as per standard of care.
  • Enrolled in another clinical trial of an investigational agent, device, or vaccine.
  • Receipt of an investigational agent or chemotherapy (active malignancy) within 30 days prior to study entry.
  • Adult-participant or fetus has any condition that, in the opinion of the site investigator or designee, would make participation in the study unsafe, complicate interpretation of study outcome data, or otherwise interfere with achieving the study objectives.

Trial locations and contacts

8 sites in 2 countries.

8 sites in 2 countries

United States4 sites

  • Site 5092, Johns Hopkins University, Baltimore

    Baltimore, Maryland, 21287

  • Site 4601, University of California, UC San Diego CRS- Mother-Child-Adolescent HIV Program

    La Jolla, California, 92093-0672

  • Site 5048, University of Southern California LA

    Los Angeles, California, 90033

  • Site 5013, Jacobi Medical Center Bronx

    The Bronx, New York, 10461

Other trials in United States

South Africa4 sites

  • Site 8051 - Wits RHI Shandukani Research Centre

    Johannesburg, 2001

  • Site 8052, Soweto

    Johannesburg

  • Site 8950, FAMCRU CRS

    Parow, 7505

  • Site 30300, Umlazi Clinical Research Site

    Umlazi, 4066

Other trials in South Africa

About this study

Official title: Phase I/II Study of the Pharmacokinetics and Safety of Long-Acting Injectable Cabotegravir and Rilpivirine in Pregnant and Postpartum Adults With HIV-1

This is a Phase I/II, multicenter, open-label, non-randomized study with four groups to characterize the pharmacokinetics and safety of Cabotegravir (CAB) and Rilpivirine (RPV) long-acting injectable (LA) during pregnancy and postpartum among people with HIV-1 viral suppression and their infants.

Being tested
CAB LA 600mg, RPV LA 900mg, CAB LA 400mg, RPV LA 600mg
Keywords
Pregnancy, Long-acting, cabotegravir, rilpivirine, pharmocokinetics, chestfeeding, breastfeeding
Medical subject headings
Breast Feeding

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • CAB LA 600mgDrug

    600mg (3mL) IM Injection

  • RPV LA 900mgDrug

    900mg (3mL) IM Injection

  • CAB LA 400mgDrug

    400mg (2mL) IM Injection

  • RPV LA 600mgDrug

    600mg (2mL) IM injection

Study groups in NCT06336434
Study groupRoleWhat they receive
Q4W SwitchExperimentalPregnant people between 10 0/7 and 19 4/7 weeks gestation with HIV-1 viral suppression on oral antiretroviral therapy willing to switch to an every four week (Q4W) CAB LA + RPV LA regimen.
Receives: Drug: CAB LA 600mg; Drug: RPV LA 900mg; Drug: CAB LA 400mg; Drug: RPV LA 600mg
Q8W SwitchExperimentalPregnant people between 10 0/7 and 19 4/7 weeks gestation with HIV-1 viral suppression on oral antiretroviral therapy willing to switch to an every eight week (Q8W) CAB LA + RPV LA regimen.
Receives: Drug: CAB LA 600mg; Drug: RPV LA 900mg
Q4W ContinuationExperimentalPregnant people 19 4/7 weeks gestation or less with HIV-1 viral suppression who were using every 4 week CAB LA + RPV LA at and since conception and are willing to continue their current CAB LA + RPV LA regimen.
Receives: Drug: CAB LA 400mg; Drug: RPV LA 600mg
Q8W ContinuationExperimentalPregnant people between 10 0/7 and 19 4/7 weeks gestation with HIV-1 viral suppression who were using every 8 week CAB LA + RPV LA at and since conception and are willing to continue their current CAB LA + RPV LA regimen.
Receives: Drug: CAB LA 600mg; Drug: RPV LA 900mg

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. PK trough of CAB LA measured in plasma in pregnancy and postpartum

    Measured: Through 18 weeks post-partum

  2. Percentage of adults with at least one Grade 3 or higher adverse event in pregnancy and through 18 weeks postpartum

    Measured: Through 18 weeks post-partum

  3. Percentage of adults with at least one serious adverse event in pregnancy and through 18 weeks postpartum

    Measured: Through 18 weeks post-partum

Secondary outcomes (22)

  1. PK trough measured in plasma in pregnancy and postpartum

    Measured: Through 18 weeks postpartum

  2. Percentage of adults with HIV-1 RNA less than 50 copies/mL at delivery

    Measured: Through Delivery

  3. Percentage of adults with HIV-1 RNA less than 50 copies/mL at delivery using the standardized FDA snapshot algorithm

    Measured: Through Delivery

  4. Percentage of adults with virologic escape (single measurement of greater than or equal to 200 copies/mL) from study entry through pregnancy and through 18 weeks postpartum

    Measured: Through 18 weeks postpartum

  5. Percentage of adults with confirmed virologic failure through 18 weeks postpartum

    Measured: Through 18 weeks postpartum

  6. Number of adults with HIV-1 resistance to CAB and/or RPV using IAS-USA in participants who experience confirmed virologic failure, assessed at entry and time of failure

    Measured: Through 18 weeks postpartum

  7. Number of infants with HIV-1 infection

    Measured: Birth through 18 weeks post birth

  8. Percentage of infants at least one Grade 3 or higher adverse event through 18 weeks post-birth

    Measured: Through 18 weeks post-birth

  9. Percentage of infants at least one serious adverse event through 18 weeks post-birth

    Measured: Through 18 weeks post-birth

  10. Percentage of infants with a congenital anomaly consistent with the Metropolitan Atlanta Congenital Defects Program (MACDP) definition of defect

    Measured: Through 18 weeks post-birth

  11. Percentage of deaths among infants

    Measured: Through 18 weeks post-birth

  12. Percentage of adults with a spontaneous abortion (less than 20 weeks gestation)

    Measured: Through delivery

  13. Percentage of adults with a fetal demise/stillbirth (greater than or equal to 20 weeks gestation)

    Measured: Through Delivery

  14. Percentage of neonatal deaths (within 28 days of life) among infants

    Measured: Through 28 days of life

  15. Percentage of infants born small for gestational age (SGA) at < 10th percentile

    Measured: Through pregnancy outcome/birth

  16. Percentage of infants born with low birth weight < 2500 g

    Measured: Through pregnancy outcome/birth

  17. Percentage of infants born preterm < 37 weeks gestation

    Measured: Through pregnancy outcome/birth

  18. Percentage of adult-infant participant pairs with any adverse pregnancy outcome of spontaneous abortion, fetal demise/stillbirth, neonatal death, SGA, or preterm delivery

    Measured: Through 28 days post-birth

  19. CAB and RPV plasma concentrations in infants exposed to CAB LA + RPV LA during pregnancy and via chest/breastfeeding

    Measured: Through 18 weeks post-birth

  20. Percentage of adults who discontinued injections prior to receiving the full course of injections due to intolerability of injection

    Measured: Through 18 weeks postpartum

  21. Frequency of CAB LA + RPV LA injections received

    Measured: Through 18 weeks postpartum

  22. Percentage of adults willing to continue CAB LA + RPV LA postpartum and/or in future pregnancies

    Measured: Through 18 weeks postpartum

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted28 Mar 2024
  2. Study start1 May 2025 (estimated)
  3. Primary completion30 Jan 2028 (estimated)
  4. Study completion30 Jan 2028 (estimated)

Why it stopped: Due to shifting priorities and reduced funding, the IMPAACT Network is not able to continue efforts toward opening IMPAACT 2040.

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 1/2
Primary purpose
Treatment
Allocation
Non-randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
0 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06336434
Sponsor's protocol ID
IMPAACT 2040
Status last verified
Jul 2025
First submitted
21 Mar 2024
Last updated
31 Jul 2025
Results posted
No
FDA-regulated drug
Yes
FDA-regulated device
No
Individual data sharing
Yes: Individual participant data that underlie results in the publication, after deidentification.

Questions about this trial

What is this clinical trial studying?

A Phase 1/2 study testing CAB LA 600mg, RPV LA 900mg and CAB LA 400mg in people with HIV-1-infection and Pregnancy, run by National Institute of Allergy and Infectious Diseases (NIAID) at 8 sites in 2 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 52 inclusion and 38 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: withdrawn, as of the sponsor's last update on 31 Jul 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 8 sites in United States, South Africa. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this combined phase mean?

Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study was withdrawn before enrolling participants, so there are no results.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

PK trough of CAB LA measured in plasma in pregnancy and postpartum (time frame: Through 18 weeks post-partum). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT06336434.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 31 Jul 2025.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in